UA116801C2 - ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 - Google Patents

ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2

Info

Publication number
UA116801C2
UA116801C2 UAA201510730A UAA201510730A UA116801C2 UA 116801 C2 UA116801 C2 UA 116801C2 UA A201510730 A UAA201510730 A UA A201510730A UA A201510730 A UAA201510730 A UA A201510730A UA 116801 C2 UA116801 C2 UA 116801C2
Authority
UA
Ukraine
Prior art keywords
pyrrolo
receptor agonists
pyrimidine derivatives
compound
formula
Prior art date
Application number
UAA201510730A
Other languages
English (en)
Inventor
Уве ГРЕТЕР
Ацусі Кімбара
Маттіас Неттекофен
Штефан Рьофер
Марк Роджерс-Еванс
Танья ШУЛЬЦ-ГАШ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA116801C2 publication Critical patent/UA116801C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Даний винахід стосується сполуки формули (І) EMBED ISISServer , (I) де А і R1-R3 є такими, як визначено в описі і формулі винаходу. Сполука формули (І) може бути використана як лікарський засіб.
UAA201510730A 2013-05-02 2014-04-29 ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 UA116801C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (1)

Publication Number Publication Date
UA116801C2 true UA116801C2 (uk) 2018-05-10

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201510730A UA116801C2 (uk) 2013-05-02 2014-04-29 ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2

Country Status (35)

Country Link
US (1) US9580435B2 (uk)
EP (1) EP2991988B1 (uk)
JP (1) JP6454689B2 (uk)
KR (1) KR20160002857A (uk)
CN (1) CN105164133B (uk)
AR (1) AR096153A1 (uk)
AU (1) AU2014261546B2 (uk)
BR (1) BR112015027394A8 (uk)
CA (1) CA2907691A1 (uk)
CL (1) CL2015003196A1 (uk)
CR (1) CR20150555A (uk)
CY (1) CY1119114T1 (uk)
DK (1) DK2991988T3 (uk)
EA (1) EA028123B1 (uk)
ES (1) ES2635632T3 (uk)
HK (1) HK1213559A1 (uk)
HR (1) HRP20171099T1 (uk)
HU (1) HUE035333T2 (uk)
IL (1) IL242162B (uk)
LT (1) LT2991988T (uk)
MA (1) MA38555B1 (uk)
MX (1) MX2015014081A (uk)
MY (1) MY182237A (uk)
NZ (1) NZ712030A (uk)
PE (1) PE20160039A1 (uk)
PH (1) PH12015502409B1 (uk)
PL (1) PL2991988T3 (uk)
PT (1) PT2991988T (uk)
RS (1) RS56313B1 (uk)
SG (1) SG11201509029PA (uk)
SI (1) SI2991988T1 (uk)
TW (1) TWI680129B (uk)
UA (1) UA116801C2 (uk)
WO (1) WO2014177527A1 (uk)
ZA (1) ZA201507008B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3483163T (pt) 2013-09-06 2021-08-24 Hoffmann La Roche Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2
EP3215506B1 (en) * 2014-11-07 2019-01-02 F.Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
CN109311895B (zh) 2016-06-23 2021-06-18 豪夫迈·罗氏有限公司 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物
JP7090037B2 (ja) 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
EP4108665A1 (en) 2016-06-23 2022-12-28 F. Hoffmann-La Roche AG [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
EP3475281A1 (en) 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR042667A1 (es) * 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
PL1999132T3 (pl) * 2006-03-30 2012-12-31 Irm Llc Azolopirymidyny jako inhibitory aktywności Receptora Kannabinoidowego typu 1
EP2155747B1 (en) * 2007-05-10 2012-10-24 GE Healthcare Limited Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2211619A1 (en) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
JP5629324B2 (ja) * 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
WO2014005968A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
EP3357918A1 (en) 2012-12-07 2018-08-08 F. Hoffmann-La Roche AG Novel pyridine derivatives
US9512141B2 (en) 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
PE20151073A1 (es) 2012-12-07 2015-07-25 Hoffmann La Roche Piridina-2-amidas utiles como agonistas de cb2
US9303012B2 (en) 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
SG11201507168XA (en) 2013-03-07 2015-10-29 Hoffmann La Roche Novel pyrazol derivatives
PL2991987T3 (pl) 2013-05-02 2018-10-31 F. Hoffmann-La Roche Ag Pochodne purynowe jako agoniści receptora CB2

Also Published As

Publication number Publication date
ZA201507008B (en) 2017-08-30
EA201591939A1 (ru) 2016-03-31
PE20160039A1 (es) 2016-01-28
IL242162B (en) 2019-06-30
EA028123B1 (ru) 2017-10-31
RS56313B1 (sr) 2017-12-29
PL2991988T3 (pl) 2017-10-31
AU2014261546B2 (en) 2018-01-18
DK2991988T3 (en) 2017-08-21
PT2991988T (pt) 2017-07-25
JP2016517874A (ja) 2016-06-20
JP6454689B2 (ja) 2019-01-16
SI2991988T1 (sl) 2017-09-29
EP2991988B1 (en) 2017-05-31
ES2635632T3 (es) 2017-10-04
TW201522343A (zh) 2015-06-16
CY1119114T1 (el) 2018-02-14
MA38555B1 (fr) 2018-04-30
MX2015014081A (es) 2015-12-11
CR20150555A (es) 2015-11-20
TWI680129B (zh) 2019-12-21
US9580435B2 (en) 2017-02-28
KR20160002857A (ko) 2016-01-08
CN105164133B (zh) 2018-02-13
CA2907691A1 (en) 2014-11-06
AU2014261546A1 (en) 2015-09-24
PH12015502409A1 (en) 2016-02-22
US20160046637A1 (en) 2016-02-18
WO2014177527A1 (en) 2014-11-06
HK1213559A1 (zh) 2016-07-08
HRP20171099T1 (hr) 2017-10-06
MA38555A1 (fr) 2017-09-29
CN105164133A (zh) 2015-12-16
MY182237A (en) 2021-01-18
AR096153A1 (es) 2015-12-09
HUE035333T2 (en) 2018-05-02
BR112015027394A2 (pt) 2017-07-25
BR112015027394A8 (pt) 2018-01-30
CL2015003196A1 (es) 2016-06-03
LT2991988T (lt) 2017-08-10
NZ712030A (en) 2021-03-26
EP2991988A1 (en) 2016-03-09
PH12015502409B1 (en) 2016-02-22
SG11201509029PA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
PH12015501843A1 (en) Novel pyrazol derivatives
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
PH12014502169A1 (en) N-cyclylamides as nematicides
PH12015501083B1 (en) Novel pyridine derivatives
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
PH12015501073A1 (en) Novel pyridine derivatives
MX363458B (es) Nuevos derivados de tetrazolona.